
President Donald Trump signed a sweeping executive order on 18 April 2026 directing federal agencies to fast-track the review, funding and potential reclassification of psychedelic drugs including psilocybin and ibogaine as treatments for serious mental illness.
The order, titled 'Accelerating Medical Treatments for Serious Mental Illness,' instructs the Food and Drug Administration to issue National Priority Vouchers to qualifying psychedelic compounds already granted Breakthrough Therapy designation, allowing their review to proceed in a matter of weeks rather than years.